Announced details
Treatment of adult patients with moderate-to-severe plaque psoriasis; dermatological diseases in Japan.
More than 1,509 patients transitioned to ONWARD3, 773 continued treatment for up to 48 weeks, 75% achieved PASI 90 at week 48, 54% achieved PASI 100, and maintenance of skin clearance was approximately 90% among patients enrolled with PASI 90 and approximately 80% among patients enrolled with PASI 100.
More than 85% of the 1,509 patients from ONWARD1/2 transitioned to ONWARD3. A total of 773 patients continued treatment with ESK-001 for up to 48 weeks.
Kaken Pharmaceutical holds the exclusive development, manufacturing and marketing rights for ESK-001 for dermatological diseases in Japan.
A Nasdaq-listed biotechnology company headquartered in South San Francisco, California, United States. Its chief executive officer is Martin Babler. The company is developing oral therapies and other treatments for immune-mediated diseases.
ONWARD1: NCT06586112; ONWARD2: NCT06588738. Other information: Not disclosed
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
Alumis Inc.'s announcement dated 10 August 2026 (US Pacific Time). Kaken Pharmaceutical stated that readers should refer to the company's announcement.
| Item | Details |
|---|---|
| Names of Products / Services Covered | ESK-001, envudeucitinib, ONWARD3 |
| Counterparty | Alumis Inc. (Alumis; Nasdaq: ALMS) |
| Counterparty overview | A Nasdaq-listed biotechnology company headquartered in South San Francisco, California, United States. Its chief executive officer is Martin Babler. The company is developing oral therapies and other treatments for immune-mediated diseases. |
| Relationship with the Company | Kaken Pharmaceutical holds the exclusive development, manufacturing and marketing rights for ESK-001 for dermatological diseases in Japan. |
| Contract Date | 25 March 2025 (the date of publication of the notice regarding the execution of the collaboration and license agreement) |
| Applicable area | Treatment of adult patients with moderate-to-severe plaque psoriasis; dermatological diseases in Japan. |
| Registration number and expiry date | ONWARD1: NCT06586112; ONWARD2: NCT06588738. Other information: Not disclosed |
| Quantitative Effects | More than 1,509 patients transitioned to ONWARD3, 773 continued treatment for up to 48 weeks, 75% achieved PASI 90 at week 48, 54% achieved PASI 100, and maintenance of skin clearance was approximately 90% among patients enrolled with PASI 90 and approximately 80% among patients enrolled with PASI 100. |
| Usage history | More than 85% of the 1,509 patients from ONWARD1/2 transitioned to ONWARD3. A total of 773 patients continued treatment with ESK-001 for up to 48 weeks. |
| Source | Alumis Inc.'s announcement dated 10 August 2026 (US Pacific Time). Kaken Pharmaceutical stated that readers should refer to the company's announcement. |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Alumis announced preliminary results from ONWARD3. More than 85% of the 1,509 patients who transitioned from ONWARD1/2 entered the study, and 773 continued treatment for up to 48 weeks.